# Amoxicillin + clavulanic acid

**Indication:** Acute sinusitis  
**ICD11 code:** CA01

**INN:** Amoxicillin + clavulanic acid

**Medicine type:** Chemical agent

**Antibiotic groups:** ACCESS

**List type:** Core (EML) (EMLc)

**Formulations**
- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid (EMLc); 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid (EMLc)
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt) (EMLc); 250 mg (as trihydrate) + 62.5 mg (as potassium salt) (EMLc)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt) (EML)

**EML status history**
- First added in 2017 (TRS 1006)
- Changed in 2023 (TRS 1049)

**Sex:** All

**Age:** Also recommended for children

**Therapeutic alternatives**
- The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions  
Read more about patents.

**Wikipedia**
- Amoxicillin + clavulanic acid

**DrugBank**
- Amoxicillin (Clavulanate)

---

### Expert Committee recommendation

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:

1. The addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc.
2. The addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc.

---

### EML recommendations: Acute sinusitis

**First choice**

**Second choice**
<table>
<thead>
<tr>
<th>Amoxicillin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxicillin + Clavulanic Acid</td>
</tr>
</tbody>
</table>